Last edition
News about
Chugai Launches Elevidys Gene Therapy for Duchenne Muscular Dystrophy in Japan
Elevidys receives conditional approval and NHI listing for ambulatory DMD patients aged three to under eight years; launch backed by Phase III EMBARK study and strengthened safety measures.
Boehringer Ingelheim India and NIPER Raebareli Sign MoU to Boost Pharma Education and Research
The MoU between NIPER Raebareli and Boehringer Ingelheim establishes a framework to strengthen academic and research collaboration in areas such as pharmaceutical technologies, novel drug delivery systems, joint research initiatives, academic exchange and capability-building programmes.
India-Rwanda Discussions Focus on AI, Bio-Manufacturing and Emerging Technologies
Union Minister Dr Jitendra Singh held talks with Rwanda’s ICT leadership to explore collaboration in Artificial Intelligence (AI), genomics, nuclear energy and deep-tech, highlighting startup partnerships and knowledge exchange to strengthen India-Rwanda cooperation.
CDSCO Flags 240 Drug Samples as Not of Standard Quality in January 2026
Central Drugs Standard Control Organisation has reported that 240 drug samples tested across India in January 2026 were found to be Not of Standard Quality (NSQ). Of these, 68 samples were identified by Central Drugs Laboratories, while 172 were flagged by State Drugs Testing Laboratories.
Andera Partners Targets EUR 10 Billion AUM as It Accelerates Innovation and European Expansion
Andera Partners is reinforcing its long-term growth strategy by combining sustained investment activity, active portfolio management and strong fundraising momentum, despite a challenging economic environment marked in 2025 by a global slowdown and a more than 20 percent decline in private equity investments in France.
<br />
BriaPro to Acquire Worldwide Rights to Soluble CD80 Immunotherapy from BriaCell
BriaCell Therapeutics Corporation and its majority-owned subsidiary BriaPro Therapeutics Corporation have entered into a definitive purchase agreement under which BriaPro will acquire BriaCell’s exclusive license to develop and commercialize Soluble CD80 (sCD80) as a biologic therapy for cancer, along with related assets.
BYSANTI (milsaperidone), a new atypical antipsychotic from Vanda Pharmaceuticals, gains FDA approval for acute manic or mixed episodes in bipolar I disorder and schizophrenia in adults, with US launch planned for Q3 2026.
IBA and Shreeji Sign Multi-Site Deal to Deploy Four Cyclotrons Across India
Ion Beam Applications S.A. (IBA), a global leader in particle accelerator technology and nuclear medicine solutions, has signed a multi-site agreement with Shreeji Imaging and Diagnostic Centre Pvt. Ltd. for the delivery and installation of four Cyclone KIUBE 300 cyclotrons in India.
Shield Therapeutics secures expanded U.S. Food and Drug Administration approval for ACCRUFeR (ferric maltol) to treat iron deficiency in pediatric patients aged 10 and above, addressing a major unmet need.
NOVOS Reports Positive Clinical Trial Results Showing Improvements in Vascular Aging Markers
A randomised clinical trial led by the University of Surrey found that NOVOS Core significantly improved endothelial function, arterial flexibility and systolic blood pressure in adults over 40 compared with placebo.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy